Cardinal Health, Inc.
Cardinal Health, Inc. (CAH) is a major US healthcare services and products company, with a market capitalisation near $37.7 billion. It operates large-scale pharmaceutical distribution and supplies medical-surgical products to hospitals, pharmacies and clinics, while also developing higher‑margin device and services offerings. Investors should know the business combines high-volume, low-margin distribution with targeted growth in medical products, so operational efficiency, inventory management and contract terms are key profit levers. The company faces sector-specific risks including reimbursement pressure, hospital budget cycles, regulatory scrutiny and strong competition from peers. Recent strategic emphasis has been on margin improvement, specialty products and supply-chain resilience, though execution and healthcare demand trends will matter. This is general educational information, not personalised advice; values can rise or fall and past performance is no guarantee of future results. Consider how exposure to healthcare distribution fits your risk tolerance and investment horizon before acting.
Why It's Moving
Cardinal Health rallies after stronger-than-expected quarter and bigger FY26 profit guide, driven by MSO deal and cash return plans
Shares moved this week after Cardinal Health reported fiscal results and guidance that beat expectations and signaled faster margin expansion across its distribution and services businesses. Management’s Solaris Health acquisition and an enhanced buyback/dividend posture convinced investors the company can convert recent operational gains into higher shareholder returns.
- Earnings and guide: Cardinal reported a quarter with meaningful profit growth and raised its FY26 non‑GAAP EPS outlook, implying stronger margin recovery across its segments and lifting investor confidence in sustainable earnings power.
- M&A accelerant: Management said it expects to close the Solaris Health urology MSO acquisition soon, positioning Cardinal to expand higher‑margin services revenue and accelerate consolidation in physician‑practice enablement.
- Capital allocation: The company initiated/expanded cash returns (including an accelerated share repurchase program and a higher dividend), signalling management’s confidence in free cash flow and boosting near‑term EPS accretion expectations.
Cardinal Health rallies after stronger-than-expected quarter and bigger FY26 profit guide, driven by MSO deal and cash return plans
Shares moved this week after Cardinal Health reported fiscal results and guidance that beat expectations and signaled faster margin expansion across its distribution and services businesses. Management’s Solaris Health acquisition and an enhanced buyback/dividend posture convinced investors the company can convert recent operational gains into higher shareholder returns.
- Earnings and guide: Cardinal reported a quarter with meaningful profit growth and raised its FY26 non‑GAAP EPS outlook, implying stronger margin recovery across its segments and lifting investor confidence in sustainable earnings power.
- M&A accelerant: Management said it expects to close the Solaris Health urology MSO acquisition soon, positioning Cardinal to expand higher‑margin services revenue and accelerate consolidation in physician‑practice enablement.
- Capital allocation: The company initiated/expanded cash returns (including an accelerated share repurchase program and a higher dividend), signalling management’s confidence in free cash flow and boosting near‑term EPS accretion expectations.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Cardinal Health's stock, anticipating its price will rise to $218.6.
Financial Health
Cardinal Health is producing solid profits and cash flow, bolstered by strong revenue generation.
Dividend
Cardinal Health's low dividend yield of 1% indicates limited income for investors. If you invested $1000 you would be paid $10 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring CAH
Pharmaceutical Policy Shift Explained | Pricing Models
The Trump administration's recent drug pricing agreements with major pharmaceutical companies like AstraZeneca and Pfizer aim to lower U.S. drug costs by tying them to international prices. This creates a potential investment opportunity in pharmaceutical firms with strong domestic production and those in the healthcare supply chain that can adapt to the new pricing landscape.
Published: October 12, 2025
Explore BasketDomestic Pharma Tariffs: What's Next for Investors
The U.S. government has imposed a 100% tariff on pharmaceuticals from companies lacking domestic manufacturing, aiming to reshore production. This policy creates a significant advantage for U.S.-based pharmaceutical companies and their supply chains, which are poised for growth as reliance on imports decreases.
Published: September 26, 2025
Explore BasketWalgreens Restructuring Explained: Investment Shifts
Following its acquisition by Sycamore Partners, Walgreens has gone private and split into five companies. This theme explores the investment opportunities created by the newly independent healthcare and retail entities.
Published: September 2, 2025
Explore BasketWalgreens' Restructuring: A New Healthcare Landscape
Following its $10 billion acquisition by Sycamore Partners, Walgreens is going private and splitting into five separate companies. This major restructuring of a key industry player could create significant opportunities for competitors and specialized healthcare service providers to capture market share.
Published: August 29, 2025
Explore BasketNavigating U.S. Drug Price Reforms
The White House is demanding major pharmaceutical companies slash U.S. drug prices, creating significant market volatility and threatening industry profits. This creates a potential opening for companies that offer cost-saving alternatives, such as generic drug makers and healthcare service providers.
Published: August 5, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Scale & Distribution
A wide distribution network underpins revenue through volume, but margins are typically thin so operational efficiency is essential.
Higher‑Margin Push
Growth in medical devices and services aims to lift margins, though execution risk and competitor response are important considerations.
Regulation & Cycles
Reimbursement trends, hospital spending cycles and regulatory changes can materially affect performance, and returns may vary over time.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
Amgen Inc.
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
ADMA BIOLOGICS INC
Develops products to treat immune deficiencies and chronic diseases.
